Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial.

@article{Amparo2013TopicalI1,
  title={Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial.},
  author={Francisco Amparo and Mohammad H Dastjerdi and Andre Okanobo and Giulio Ferrari and Leila Smaga and Pedram Hamrah and Ula V Jurkunas and Debra A. Schaumberg and Reza Dana},
  journal={JAMA ophthalmology},
  year={2013},
  volume={131 6},
  pages={715-723}
}
IMPORTANCE The immunopathogenic mechanisms of dry eye disease (DED), one of the most common ophthalmic conditions, is incompletely understood. Data from this prospective, double-masked, randomized trial demonstrate that targeting interleukin 1 (IL-1) by topical application of an IL-1 antagonist is efficacious in significantly reducing DED-related patient symptoms and corneal epitheliopathy. OBJECTIVE To evaluate the safety and efficacy of treatment with the topical IL-1 receptor antagonist… CONTINUE READING
27 Citations
42 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 42 references

Evaluation of topical cyclosporine JAMA OPHTHALMOL/ VOL 131 (NO

  • HD Perry, R Solomon, ED Donnenfeld
  • JUNE 2013 WWW.JAMAOPHTH.COM
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…